Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232192 | 0.90 | F10 (0.67) | F10ABCB11F2ST14 | |
| SCHEMBL13232196 | 0.90 | F10 (0.66) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13232237 | 0.84 | F10 (0.70) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13232242 | 0.81 | F10 (0.68) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13232241 | 0.81 | F10 (0.63) | F10ABCB11F2ST14 | |
| SCHEMBL13232238 | 0.81 | F10 (0.63) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13232202 | 0.80 | F10 (0.64) | F10ABCB11F2ST14 | |
| SCHEMBL13232191 | 0.80 | F10 (0.69) | F10ABCB11F2ST14 | |
| SCHEMBL13232227 | 0.79 | F10 (0.68) | F10ABCB11F2ST14 | |
| SCHEMBL4761184 | 0.79 | F10 (0.64) | F10ABCB11F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288423-B2 | FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-10-16 | — | — | US | disclosed |
| US-8288423-B2 | FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-10-16 | — | — | US | disclosed |
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-07-22 | — | — | US | disclosed |
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | F12, F2, TFPI | F10 4/4885CYP1A2 287/4885CYP3A4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.